NR4A1 and invasive breast carcinoma: A study by the Breast International Group based on clinical trial data of 7963 postmenopausal women with early stage hormone receptor-positive invasive breast cancer showed that initiation of cholesterol-lowering medications during any endocrine therapy was associated with improved disease-free survival compared to never users (HR 0.79, 95% CI 0.66–0.95) [33].